This method facilitated: [1] revealing 6 subtypes of γδ T cells (C10-γδ-TCF, C11-γδ-GZMK, C12-γδ-TNF, C13-γδ-GNLY and C14-γδ-TIGIT.1 and C14-γδ-TIGIT.2) [2], observing the heterogeneity in gene expression among γδ T cell subtypes [3], hypothesizing different roles of each γδ T cell subtype (stemness [27], memory T cell function [28], activation [29], cytotoxicity [30, 31], immunosuppression [32, 33], etc.)[4] predicting the differentiation trajectory of γδ T cells, and exploring a potential relationship between TIGIT+ γδ T cells and negative outcomes in DLBCL patients. The gene discussed is GZMK; the disease is diffuse large B-cell lymphoma.